0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%
Last update at 2024-12-19T16:37:00Z
Haleon Canada Donates Children's Advil to Organizations in Need
Wed 09 Oct 24, 12:00 PMHLN or PODD: Which Is the Better Value Stock Right Now?
Thu 03 Oct 24, 03:40 PMPfizer to Pare Haleon Stake With 540 Million Share Offering
Mon 30 Sep 24, 05:58 PMPfizer to offload about 6% stake in Sensodyne-maker Haleon, says bookrunner
Mon 30 Sep 24, 04:14 PMPfizer to sell about $3.25 billion stake in Sensodyne-maker Haleon, bookrunner says
Mon 30 Sep 24, 04:14 PMDrug giant Pfizer sells $3.3 billion stake in Sensodyne-maker Haleon
Mon 30 Sep 24, 04:14 PMEstimating The Fair Value Of Haleon plc (LON:HLN)
Fri 13 Sep 24, 10:56 AMQuestor: Further FTSE 100 outperformance lies ahead for this maker of household names
Mon 02 Sep 24, 07:00 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | 1618.00M | 1636.00M | 1591.00M | 886.00M |
| Minority interest | - | -49.00000M | -36.00000M | -32.00000M |
| Net income | 1060.00M | 1390.00M | 1145.00M | 655.00M |
| Selling general administrative | 4483.00M | 4086.00M | 4220.00M | 3596.00M |
| Selling and marketing expenses | - | - | - | - |
| Gross profit | 6577.00M | 5950.00M | 5910.00M | 4802.00M |
| Reconciled depreciation | - | 268.00M | 305.00M | 260.00M |
| Ebit | 1825.00M | 1638.00M | 1598.00M | 897.00M |
| Ebitda | 2163.00M | 1951.00M | 1905.00M | 1176.00M |
| Depreciation and amortization | 338.00M | 313.00M | 307.00M | 279.00M |
| Non operating income net other | - | - | - | - |
| Operating income | 1825.00M | 1638.00M | 1598.00M | 897.00M |
| Other operating expenses | 9033.00M | 7907.00M | 8294.00M | 7583.00M |
| Interest expense | 258.00M | 12.00M | 15.00M | 26.00M |
| Tax provision | 499.00M | 197.00M | 410.00M | 199.00M |
| Interest income | 5.00M | 34.00M | 31.00M | 24.00M |
| Net interest income | - | -2.00000M | -9.00000M | -10.00000M |
| Extraordinary items | - | - | - | - |
| Non recurring | - | - | - | - |
| Other items | - | - | - | - |
| Income tax expense | 499.00M | 197.00M | 410.00M | 199.00M |
| Total revenue | 10858.00M | 9545.00M | 9892.00M | 8480.00M |
| Total operating expenses | 4752.00M | 4312.00M | 4312.00M | 3905.00M |
| Cost of revenue | 4281.00M | 3595.00M | 3982.00M | 3678.00M |
| Total other income expense net | -207.00000M | -2.00000M | -7.00000M | -11.00000M |
| Discontinued operations | - | - | - | - |
| Net income from continuing ops | - | 1439.00M | 1181.00M | 687.00M |
| Net income applicable to common shares | 1060.00M | 1390.00M | 1145.00M | - |
| Preferred stock and other adjustments | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 34815.00M | 34451.00M | 34130.00M | 35711.00M |
| Intangible assets | 20040.00M | 18949.00M | 18953.00M | 19841.00M |
| Earning assets | - | - | - | - |
| Other current assets | - | 61.00M | 135.00M | 266.00M |
| Total liab | 18358.00M | 7971.00M | 7907.00M | 8299.00M |
| Total stockholder equity | 16331.00M | 26355.00M | 26112.00M | 27321.00M |
| Deferred long term liab | - | - | - | - |
| Other current liab | 312.00M | 1954.00M | 2281.00M | 2540.00M |
| Common stock | 92.00M | 1.00M | 1.00M | 1.00M |
| Capital stock | - | 1.00M | 1.00M | 1.00M |
| Retained earnings | 26730.00M | 37986.00M | 37763.00M | 5106.00M |
| Other liab | - | - | - | - |
| Good will | 8396.00M | 8246.00M | 8265.00M | 8171.00M |
| Other assets | - | - | - | - |
| Cash | 684.00M | 414.00M | 334.00M | 340.00M |
| Cash and equivalents | - | - | - | - |
| Total current liabilities | 4370.00M | 4238.00M | 4014.00M | 4269.00M |
| Current deferred revenue | - | 11.00M | 11.00M | 7.00M |
| Net debt | 9756.00M | 577.00M | 153.00M | 302.00M |
| Short term debt | 437.00M | 904.00M | 382.00M | 521.00M |
| Short long term debt | - | 874.00M | 348.00M | 481.00M |
| Short long term debt total | 10440.00M | 991.00M | 487.00M | 642.00M |
| Other stockholder equity | -10491.00000M | - | - | 20842.00M |
| Property plant equipment | - | - | - | - |
| Total current assets | 4059.00M | 5251.00M | 5008.00M | 5811.00M |
| Long term investments | - | - | - | - |
| Net tangible assets | - | - | - | - |
| Short term investments | - | 1.00M | 1.00M | 1.00M |
| Net receivables | - | 3825.00M | 3590.00M | 3994.00M |
| Long term debt | - | - | - | - |
| Inventory | 1348.00M | 951.00M | 949.00M | 1211.00M |
| Accounts payable | 3621.00M | 1369.00M | 1340.00M | 1201.00M |
| Total permanent equity | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - |
| Accumulated other comprehensive income | - | -11632.00000M | -11652.00000M | 1372.00M |
| Additional paid in capital | - | - | - | - |
| Common stock total equity | - | - | - | - |
| Preferred stock total equity | - | - | - | - |
| Retained earnings total equity | - | - | - | - |
| Treasury stock | - | - | - | - |
| Accumulated amortization | - | - | - | - |
| Non currrent assets other | 132.00M | 8.00M | 10.00M | 10.00M |
| Deferred long term asset charges | - | - | - | - |
| Non current assets total | 30756.00M | 29200.00M | 29122.00M | 29900.00M |
| Capital lease obligations | - | 117.00M | 139.00M | 161.00M |
| Long term debt total | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | - | -33.00000M | 1030.00M | 291.00M |
| Change to liabilities | - | - | - | - |
| Total cashflows from investing activities | - | - | - | - |
| Net borrowings | - | - | - | - |
| Total cash from financing activities | 6911.00M | -1236.00000M | -2437.00000M | -925.00000M |
| Change to operating activities | - | - | - | - |
| Net income | 1119.00M | 1439.00M | 1181.00M | 687.00M |
| Change in cash | 205.00M | 82.00M | -6.00000M | 138.00M |
| Begin period cash flow | 406.00M | 323.00M | 329.00M | 191.00M |
| End period cash flow | 611.00M | 405.00M | 323.00M | 329.00M |
| Total cash from operating activities | 2063.00M | 1356.00M | 1407.00M | 786.00M |
| Issuance of capital stock | - | - | - | - |
| Depreciation | 287.00M | 268.00M | 305.00M | 260.00M |
| Other cashflows from investing activities | - | - | - | - |
| Dividends paid | 2682.00M | 1148.00M | 2371.00M | 1152.00M |
| Change to inventory | -292.00000M | -17.00000M | 130.00M | 232.00M |
| Change to account receivables | - | 14.00M | 18.00M | -57.00000M |
| Sale purchase of stock | - | - | - | - |
| Other cashflows from financing activities | 11111.00M | -88.00000M | -56.00000M | 227.00M |
| Change to netincome | - | - | - | - |
| Capital expenditures | 328.00M | 298.00M | 318.00M | 243.00M |
| Change receivables | - | - | - | - |
| Cash flows other operating | - | - | - | - |
| Exchange rate changes | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - |
| Change in working capital | 181.00M | -152.00000M | 15.00M | -461.00000M |
| Stock based compensation | - | -376.00000M | -702.00000M | -261.00000M |
| Other non cash items | 476.00M | -20.00000M | 198.00M | 362.00M |
| Free cash flow | 1735.00M | 1058.00M | 1089.00M | 543.00M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HLN Haleon PLC |
-3.3 0.86% | 380.60 | 24.73 | 16.86 | 2.63 | 1.81 | 3.17 | 16.57 |
| HIK Hikma Pharmaceuticals PLC |
7.00 0.36% | 1935.00 | 33.45 | 11.14 | 1.45 | 2.32 | 1.76 | 8.98 |
| HCM HUTCHMED China Ltd |
2.00 0.85% | 238.00 | - | - | 3.22 | 3.97 | 2.39 | -19.4252 |
| INDV Indivior PLC |
-32.0 3.38% | 913.50 | - | - | 1.60 | 48.69 | 1.17 | -4.7616 |
| BXP Beximco Pharmaceuticals Limited |
1.20 3.29% | 37.70 | 5.86 | 4.52 | 0.01 | 0.59 | 0.01 | 0.06 |
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Weybridge, the United Kingdom.
Building 5, Weybridge, United Kingdom, KT13 0NY
| Name | Title | Year Born |
|---|---|---|
| Mr. Brian McNamara | CEO & Exec. Director | 1967 |
| Mr. Tobias Hestler | CFO & Exec. Director | 1972 |
| Ms. Amy Landucci | Head of Digital and Technology | NA |
| Mr. Bjarne Philip Tellmann | Gen. Counsel | 1967 |
| Ms. Tamara Rogers | Chief Marketing Officer | 1969 |
| Ms. Mairead Nayager | Chief HR Officer | 1975 |
| Mr. Bart Derde | Head of Quality and Supply Chain | 1969 |
| Mr. Filippo Lanzi | Head of EMEA & LatAm | NA |
| Ms. Teri Lyng | Head of Transformation & Sustainability | 1962 |
| Ms. Jooyong Lee | Head of Strategy and Office of the CEO | 1977 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...